X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Patent Protection Lift-off For COVID-19 Vaccines; Not a Bright Choice

Content Team by Content Team
2nd December 2020
in News
FSD Pharma Gets Go Ahead for Phase IIa COVID-19 Trial

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The world of Pharmaceuticals is caught in the web of who brings out the vaccine and when scenario. The darkest hours that the world has been a witness to are from the last 10 months. However, every day, there is a ray of hope which pushes us to believe that all this is soon going to end the way it should be. The much-awaited invention of a COVID-19 vaccine that gets us back on to our feet is hopefully around the corner.

As we pen this down, Pfizer and BioNtech, Moderna, AstraZeneca have all shown much promise in going the right way. The clinical trials efficacy of each of them is a testament to their success. Pharmaceutical companies have invested big time in research and development that will result in effective and to the point manufacturing during the course of this pandemic.

According to Thomas Cueni, Director General of the International Federation of Pharmaceutical Manufacturers and Associations, “Patent protection shouldn’t be lifted when it comes to building a dose as complex as this. If at all that happens, the quality assurance may take a big hit due to the involvement of the lesser expert staff as well non-compliances of the benchmarking practices”. He further adds that there is a strong probability of almost 10 vaccines coming out by next summer, but all that has to happen with rigorous, transparent and scientific scrutiny of the processes undertaken.

It is well to be noted that at the WTO level, countries such as India, South Africa have already proposed a temporary waiver when it comes to compulsory licensing for patented products. However, there has been strong opposition by USA, EU & Switzerland in this regard.

Cueni says that “There is no doubt a lot of politics is involved in this gamut of Intellectual Property and it shows a sort of disrespect to the entire pharmaceutical system that has developed with time. A minimum number of 50 quality assurance staff are required in carrying out effective monitoring and there are around hundreds of checks during the entire production process. There has never been an instance of a compulsory license being granted for a vaccine during a pandemic or otherwise and every member of the pharmaceutical fraternity have committed to a not-for-profit and socially responsible pricing matrix for COVID-19”.

Previous Post

A Go-Ahead Given By European Commission To Moderna For Supplying The Budding COVID-19 Vaccine

Next Post

Biopharma Market to grow at 10.6% CAGR between 2020 and 2027

Related Posts

FDA Accepts BLA for Recommended
FDA Approvals

FDA Accepts BLA for Recommended Biosimilar to Simponi

22nd July 2025
Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
Next Post
Charities Pay $6 Million to Settle Medicare Kickback Allegations in Pharma Probe

Biopharma Market to grow at 10.6% CAGR between 2020 and 2027

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In